Ring Nitrogen In The Pentacyclo Ring System Is Shared By Five-membered Cyclo And Six-membered Cyclo (e.g., Vincamine, Etc.) Patents (Class 514/283)
  • Publication number: 20140141089
    Abstract: The disclosure is directed to a nanoparticle comprising a porous framework core including a porous framework material and a compound, and a lipid layer disposed on the surface of the porous framework core.
    Type: Application
    Filed: February 11, 2010
    Publication date: May 22, 2014
    Applicant: Colorado School of Mines
    Inventor: Hongjun Liang
  • Patent number: 8729048
    Abstract: This document provides methods and materials involved in assessing responsiveness to PARP inhibitors and platinating agents. For example, methods and materials for using levels of non-homologous end-joining pathway members (e.g., artemis mRNA or polypeptide levels, Ku80 mRNA or polypeptide levels, or DNA-PKcs mRNA or polypeptide levels) to determine if cancer cells that are homologous recombination-deficient are likely to be susceptible or resistant to PARP inhibitors and platinating agents are provided.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: May 20, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Scott H. Kaufmann, Anand G. Patel
  • Publication number: 20140135357
    Abstract: The present invention is directed to a method of inhibiting cancer cell growth, comprising administering a pharmaceutical composition to a subject in need thereof. The pharmaceutical composition comprises at least one camptothecin derivative or a pharmaceutically acceptable salt thereof; and at least one PEG phospholipid, and provides a sustained release of topotecan as an active ingredient.
    Type: Application
    Filed: November 12, 2013
    Publication date: May 15, 2014
    Applicants: Taiwan Liposome Company, Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Yun-Long TSENG, Keelung HONG, Min-Wen KUO
  • Publication number: 20140135356
    Abstract: The present invention provides novel conjugates of camptothecin and camptothecin analogs with a linker and an HSA-binding moiety. The novel conjugates are prodrug forms of the camptothecin or camptothecin analogs and can be used to treat mammalian cell proliferative diseases, such as cancer.
    Type: Application
    Filed: November 11, 2013
    Publication date: May 15, 2014
    Applicant: FL Therapeutics, LLC
    Inventor: Qun Sun
  • Publication number: 20140134280
    Abstract: An extract of Cynanchum sp. in use of arthritis treatment is provided. The extract of Cynanchum sp. and an active ingredient contained therein, antofine, are applicable to a method, pharmaceutical composition and dietary supplement for treatment of arthritis. A mass production of antofine from plant extracts is also provided.
    Type: Application
    Filed: April 27, 2012
    Publication date: May 15, 2014
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jennline Sheu, Lain-Tze Lee, Ying-Chu Shih, Cheng-Yu Lee, Yi-Ching Lee, Jir-Mehng Lo, Tien-Soung Tong, Jui-Hung Yen, Kuo-Kuei Huang, Ying-Fei Tsai
  • Publication number: 20140134274
    Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.
    Type: Application
    Filed: October 24, 2013
    Publication date: May 15, 2014
    Applicant: University of Tennessee Research Foundation
    Inventors: Mitchell S. Steiner, Mary Ann Johnston, Michael L. Hancock, Jeffrey G. Hesselberg, James T. Dalton
  • Publication number: 20140127272
    Abstract: The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of ?-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions.
    Type: Application
    Filed: October 31, 2013
    Publication date: May 8, 2014
    Applicant: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Bong Seop Lee
  • Publication number: 20140127136
    Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of liposomal compositions to the brain.
    Type: Application
    Filed: January 9, 2014
    Publication date: May 8, 2014
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Daryl C. Drummond, Dmitri Kirpotin
  • Publication number: 20140128421
    Abstract: Provided are a camptothecin compound containing 7-membered lactone ring, as shown in general formula I, and pharmaceutically acceptable salt thereof, as well as the preparation method and use thereof. In general formula I, R1 is H, a C1˜C3 alkyl, acetyl or propionyl; R2 is H, a C1˜C6 alkyl, a C3˜C6 cycloalkyl, piperidyl; or a C1˜C6 alkyl substituted by an amino; R3 is H, a C1˜C3 alkyl, or a C1˜C6 alkyl substituted by an amino; R4 is H, a hydroxyl, or a C1˜C6 alkoxy; R5 is H, or a C1˜C6 alkoxyl; or R4 and R5 are linked to each other to form —OCH2O— or —OCH2CH2O—. The compound has good anti-tumor activity, and can be clinically used via oral administration, intravenous injection, and intramuscular injection, among others.
    Type: Application
    Filed: April 13, 2012
    Publication date: May 8, 2014
    Applicants: EAST CHINA NORMAL UNIVERSITY, NANJING LUYESKIE PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Wei Lv, Shanbao Yu, Yu Luo, Yi Chen, Jian Ding
  • Publication number: 20140120087
    Abstract: The present invention relates to triazolopyridine compounds of general formula (I): in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
    Type: Application
    Filed: April 16, 2012
    Publication date: May 1, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Volker Schulze, Dirk Kosemund, Antje Margret Wengner, Gerhard Siemeister, Detlef Stöckigt, Philip Lienau, Hartmut Schirok, Hans Briem
  • Publication number: 20140121178
    Abstract: The present invention relates to a method and an improved composition for improving the absorption of an ester prodrug in a subject. The method includes co-administering to the subject an effective amount of the ester prodrug or a pharmaceutical acceptable salt thereof, and a sufficient amount of adjuvant to impede a carboxylesterase-mediated hydrolysis of the ester prodrug in vivo, wherein the adjuvant is selected from the gnzup consisting of triacetin, triethyl citrate and a combination of both. The present invention also relates to a method for impeding carboxylesterase-mediated hydrolysis of esters, including ester prodrugs.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 1, 2014
    Applicant: ACENDA PHARMA INC.
    Inventor: Haiyung Cheng
  • Patent number: 8709419
    Abstract: The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: April 29, 2014
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Kapil Dhingra, Brian Higgins, Kenneth Kolinsky, Richard J. Lee, Brian Lestini, Kathryn Packman, Fei Su
  • Patent number: 8709474
    Abstract: The present invention relates to the use of copper ions to achieve enhanced retention of a therapeutic agent within a liposome. The invention may be employed to more effectively deliver a liposomally encapsulated therapeutic agent to a target site in vitro and in vivo for anti-cancer or other therapy. The liposome may comprise an interior buffer solution containing the therapeutic agent, the solution having a pH less than 6.5 and most preferably approximating pH 3.5. At least some of the copper ions are retained within the interior solution. In a particular embodiment the therapeutic agent may be a chemotherapeutic drug, such as irinotecan. The invention may also comprise an ionophore to facilitate loading of drug into the liposome. In one particular embodiment the combination of the ionophore A23187 and encapsulated divalent copper (Cu2+) resulted in an irinotecan formulation that exhibited surprisingly improved drug retention attributes.
    Type: Grant
    Filed: December 9, 2012
    Date of Patent: April 29, 2014
    Assignee: BC Cancer Agency
    Inventors: Marcel Bally, Euan Ramsay
  • Publication number: 20140113879
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Application
    Filed: September 16, 2013
    Publication date: April 24, 2014
    Applicant: Intezyne Technologies, Inc.
    Inventors: Adam Carie, Kevin Sill
  • Patent number: 8703181
    Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provides methods of making the liposome compositions provided by the present invention.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: April 22, 2014
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Keelung Hong, Daryl C. Drummond, Dmitri Kirpotin
  • Publication number: 20140107147
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 17, 2014
    Applicant: Wyeth LLC
    Inventor: Wyeth LLC
  • Publication number: 20140093585
    Abstract: The present invention relates to the method of treating chemotherapy-induced neuropathy in a subject in need thereof with the use of a poly(ADP-ribose)polymerase (PARP) inhibitor.
    Type: Application
    Filed: December 5, 2013
    Publication date: April 3, 2014
    Inventors: Vincent L. Giranda, Alexander R. Shoemaker, Kaitlin E. Browman, Shailen K. Joshi, Jill-Desiree Brederson
  • Patent number: 8685997
    Abstract: New camptothecin derivatives with the following structure of the formula (I), their use and the pharmaceutical compositions containing the same. The compounds of the present invention have good anti-tumor activities and good solubility in water, and can be used in development of medicines.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: April 1, 2014
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Wei Lu, Jian Ding, Heyong Gao, Liping Lin, Yi Chen
  • Publication number: 20140088133
    Abstract: The present invention provides compounds (such as compounds of formula I-a) that induce ? globin expression and pharmaceutical compositions thereof. Such compounds may have beneficial therapeutic effects. Compounds and compositions described herein may be used to treat hemoglobinopathies such as ?-thalassemia and sickle cell anemia.
    Type: Application
    Filed: January 3, 2012
    Publication date: March 27, 2014
    Applicant: Academia Sinica
    Inventors: Che-Kun James Shen, Yu-Chi Chou
  • Publication number: 20140079636
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to an binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 20, 2014
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Publication number: 20140079693
    Abstract: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
    Type: Application
    Filed: November 15, 2013
    Publication date: March 20, 2014
    Applicant: NOVARTIS AG
    Inventors: Matthew T. Burger, Wooseok Han, Jiong Lan, Gisele Nishiguchi
  • Publication number: 20140079644
    Abstract: In one aspect, there is provided a compound comprising an acetylated carboxymethylcellulose (CMC-Ac) covalently linked to: at least one poly(ethylene glycol) (PEG), and at least one hydrophobic drug. In another aspect, a self-assembling nanoparticle composition comprising such compounds is provided.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 20, 2014
    Applicant: ONTARIO INSTITUTE FOR CANCER RESEARCH
    Inventors: Shyh-Dar Li, Mark John Ernsting, Wei-Lun Tang
  • Publication number: 20140073604
    Abstract: Disclosed are compounds that are conjugates of ladder frame polyether compounds and biologically active compounds or research compounds, pharmaceutical formulations comprising the conjugates, and methods of transporting the conjugates across biological membranes.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 13, 2014
    Applicant: UNIVERSITY OF NORTH CAROLINA AT WILMINGTON
    Inventor: UNIVERSITY OF NORTH CAROLINA AT WILMINGTON
  • Patent number: 8663700
    Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: March 4, 2014
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
  • Patent number: 8663606
    Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: March 4, 2014
    Assignee: Medigene AG
    Inventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
  • Publication number: 20140056880
    Abstract: The present invention provides triazole compounds of Formula I: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound of Formula I.
    Type: Application
    Filed: August 28, 2013
    Publication date: February 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Tinya Abrams, Paul Barsanti, Yu Ding, David Duhl, Wooseok Han, Cheng Hu, Yue Pan
  • Patent number: 8652528
    Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 18, 2014
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
  • Publication number: 20140045782
    Abstract: Methods of treating cancer by administering a DNA damaging agent and a CHK1 Inhibitor on a dosing regimen are provided.
    Type: Application
    Filed: June 7, 2013
    Publication date: February 13, 2014
    Inventors: Michael J. Humphries, Shannon L. Winski
  • Publication number: 20140037620
    Abstract: The application describes methods for predicting overall survival in subjects with breast cancer. The application also describes for screening subjects with breast cancer to determine if the breast cancer will be responsive to a breast cancer therapy including gemcitabine. The application further describes methods for treating subjects with breast cancer by screening them for the likelihood of the effectiveness of treating the cancer with a therapy including gemcitabine and administering the therapy in subjects when it is found that gemcitabine is likely to be effective.
    Type: Application
    Filed: June 28, 2013
    Publication date: February 6, 2014
    Inventors: Sean M. Ferree, J. Wayne Cowens, Charlotte Levin Tykjaer Jorgensen, Torsten O. Nielsen, Bent Ejlertsen
  • Publication number: 20140037547
    Abstract: The present invention relates to cGMP protein kinase (PKG) and regulatory domains and methods of use thereof. The structural determination of PKG domains is also described. cGMP independent PKG activators and uses thereof are also described.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 6, 2014
    Applicant: The University of Vermont and State Agricultural College
    Inventors: Wolfgang Dostmann, Brent W. Osborne, Thomas M. Moon
  • Publication number: 20140030224
    Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.
    Type: Application
    Filed: April 10, 2012
    Publication date: January 30, 2014
    Applicant: UNIVERSITÉ CLAUDE BERNARD - LYON 1
    Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
  • Patent number: 8633208
    Abstract: The present invention is directed to 6-(1H-imidazo-1-yl)-2-aryl and 2-heteroaryl quinazoline and quinolines derivatives, compounds of formula (I), their pharmaceutical acceptable salts and solvates and corresponding pharmaceutical compositions, that acts as Monoamine Oxidase (MAO) inhibitors and Imidazoline Receptor ligands: wherein: X is independently selected from —CH group or a nitrogen atom (—N), W is independently selected from an aryl group, an heteroaryl group, or a benzocondensed heteroaryl group such as 1,3-benzodioxole, benzofuran, 2,3-dihydrobenzofuran, benzothiophene, 2,3-dihydrobenzothiophene, indole, 2,3-dihydroindole, benzimidazole, benzoxazole, benzothiazole, 2H-3,4-dihydrobenzopyran, [1,4]-benzodioxine, 2,3-dihydro-[1,4]-benzodioxine (1,4-benzodioxan). R1 is independently selected from hydrogen (—H), C1-C4 alkyl, hydroxymethyl (—CH2OH), aminomethyl (—CH2NH2), alkylaminomethyl [CH2NH(R2)], or di-alkylaminomethyl [CH2N(R2)2], trifluoromethyl (—CF3).
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: January 21, 2014
    Assignee: Rottapharm S.p.A
    Inventors: Antonio Giordani, Marco Lanza, Gianfranco Caselli, Stefano Mandelli, Simona Zanzola, Francesco Makovec, Lucio Claudio Rovati
  • Patent number: 8630703
    Abstract: Hydrophobic weak base compounds such as hydrophobic weak base chemotherapeutic agents (which are not an anthracycline) for use in the treatment of medical conditions such as proliferative disease or disorder in a subject, in combination with illumination of a region in a body of the subject which is characterized by the presence of proliferating cells, are disclosed. The hydrophobic weak base compound and a wavelength of illumination are selected such that the hydrophobic weak base compound acts as a therapeutically effective photosensitizer when exposed to the illumination.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: January 14, 2014
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Yehuda G. Assaraf, Yamit Adar Turgeman, Andrzej M. Skladanowski, Arjan W. Griffioen, Henk Verheul, Kristy Gotink, Hubert Van Den Bergh, Patrycja Nowak-Sliwinska
  • Publication number: 20140011833
    Abstract: Disclosed are novel camptothecin derivatives having anti-tumor activity (the basic structure thereof is as shown in the figure) and compositions of such compounds and use thereof. The compounds according to the present invention exhibit very good water solubility and stability, show good selectivity among drugs of the same category, and have a very high therapeutic index. Such compounds are promising as therapeutic agents for treating tumors.
    Type: Application
    Filed: April 6, 2012
    Publication date: January 9, 2014
    Applicant: Ningbo Team Pharmaceutical Co., Ltd
    Inventors: Xiaoguang Lei, Xiuguo Zhang
  • Publication number: 20140004192
    Abstract: The present invention relates to pharmaceutical formulations that increase the solubility and bioavailability of indibulin, such as a spray-dried solid dispersion of indibulin with at least one matrix polymer. The invention further provides dosage formulations comprising the dispersion and processes for making the dispersion. The present invention also discloses a method of treating immune system based disorders, hyper-proliferative disorders, angiogenesis, malignancies, and neoplasms with the indibulin formulations disclosed herein.
    Type: Application
    Filed: March 12, 2013
    Publication date: January 2, 2014
    Inventors: John C. Amedio, JR., Barbara Wallner, Marsha G. Marande
  • Publication number: 20140004190
    Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.
    Type: Application
    Filed: June 13, 2013
    Publication date: January 2, 2014
    Applicant: Astellas Deutschland GmbH
    Inventors: Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Ouatas, Margaretha Olthoff
  • Patent number: 8618124
    Abstract: Heterobifunctional polymeric prodrug platforms for delivering biologically active compounds, including proteins, monoclonal antibodies and the like are disclosed. One preferred compound is Methods of making and using the compounds and conjugates described herein are also provided.
    Type: Grant
    Filed: September 25, 2007
    Date of Patent: December 31, 2013
    Assignee: Belrose Pharma, Inc.
    Inventors: Richard B. Greenwald, Hong Zhao
  • Publication number: 20130345164
    Abstract: This invention concerns methods of identifying treatments for treating various disorders and related computer products and systems. Also disclosed are methods for treating cellular proliferative disorders and use of compounds identified for such treatment.
    Type: Application
    Filed: April 21, 2011
    Publication date: December 26, 2013
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Alexei Vazquez, Darren Carpizo, Arnold Levine
  • Publication number: 20130336965
    Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 20, 2013
    Publication date: December 19, 2013
    Applicant: Novartis AG
    Inventors: Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
  • Publication number: 20130336969
    Abstract: The present invention provides a method for diagnosing KRAS mutations in colorectal cancers by measuring the level of OLFM4. In another aspect, the present invention relates a method of predicting the responds to a chemotherapeutic agent of a subject suffering from a colorectal cancer: according to the present invention, the by determining the OLFM4 levels. According to the present invention, the response can be predicted by determining the OLFM4 levels. This result in turn permits the design or the adaptation of a treatment of the said subject with the said chemotherapeutic agent.
    Type: Application
    Filed: March 2, 2011
    Publication date: December 19, 2013
    Applicant: INSTITUT DE CANCEROLOGIE DE L'OUEST
    Inventors: Catherine Guette, Olivier Coqueret, Benjamin Barre, Erick Gamelin
  • Patent number: 8609860
    Abstract: The present invention relates to a compound comprising an imine bond as an acid-labile trigger group, the use of such an imine bond as an acid-labile trigger group, a process of cleaving the imine bond in said compound, and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: December 17, 2013
    Assignee: KTB Tumorforschungsgesellschaft mbH
    Inventors: André Warnecke, Ivonne Müller
  • Patent number: 8609142
    Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: December 17, 2013
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Michael Figa, Abhimanyu Sabnis
  • Publication number: 20130324494
    Abstract: Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders.
    Type: Application
    Filed: August 8, 2013
    Publication date: December 5, 2013
    Applicant: Aposense Ltd.
    Inventors: Ilan ZIV, Hagit Grimberg
  • Publication number: 20130317018
    Abstract: The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.
    Type: Application
    Filed: November 9, 2011
    Publication date: November 28, 2013
    Inventors: Benjamin David Philpot, Mark John Zylka, Bryan Leo Roth, John Arthur Allen, Hsien-Sung Huang
  • Patent number: 8592434
    Abstract: The present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: November 26, 2013
    Assignee: BioAlliance Pharma SA
    Inventors: Pierre Attali, Dominique Costantini, Caroline Lemarchand
  • Publication number: 20130303562
    Abstract: The invention relates to methods for screening and identification of compounds and compositions that are useful in the treatment of neurological disorders, for example, of polyQ tract expansion diseases, such as Huntington's Disease. The invention further relates to methods, compounds, and compositions for the treatment of a variety of neurological disorders.
    Type: Application
    Filed: December 2, 2011
    Publication date: November 14, 2013
    Applicant: Massachusetts Institute of Technology
    Inventors: Joost Schulte, Katharine Julia Sepp, J. Troy Littleton
  • Publication number: 20130295198
    Abstract: Methods for selecting chemotherapeutic agents for treating a cancer are provided that include the steps of providing a cancer cell sample having a population of bulk cancer cells and a population of cancer stem-like cells, culturing a first portion of the cancer cell sample in a hydrodynamic focusing bioreactor under microgravity conditions and for a period of time to selectively enhance the population of cancer stem-like cells and selectively kill the population of bulk cancer cells, contacting the cancer stem-like cells with one or more chemotherapeutic agents, and then selecting the one or more chemotherapeutic agents for treating the cancer if there is an increase in an amount of cytotoxicity. Methods for treating a cancer are also provided in which the identified chemotherapeutic agents are administered to a subject. Further provided are methods for identifying a test compound useful for treating a cancer.
    Type: Application
    Filed: March 19, 2013
    Publication date: November 7, 2013
    Applicant: Marshall University Research Corporation
    Inventor: Marshall University Research Corporation
  • Patent number: 8575188
    Abstract: Various 14-nitro, 14-amino, and 14-substituted amino camptothecin derivatives are useful in the treatment of cancer and other hyperproliferative diseases. 14-Nitro camptothecin derivatives are conveniently prepared by reacting a camptothecin derivative with fuming nitric acid, optionally employing acetic anhydride as a solvent.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: November 5, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Xiaohong Cai, Jian-Xin Duan, Mark Matteucci, Yeyu Cao, Hailong Jiao
  • Publication number: 20130288991
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 31, 2013
    Inventors: Kevin Sill, Tomas Vojkovsky
  • Publication number: 20130280334
    Abstract: Self-assembled gel compositions including a gelator, e.g., an enzyme-cleavable gelator, e.g., having a molecular weight of 2500 or less, are described. The self-assembled gel compositions can encapsulate one or more agents. Methods of making the self-assembled gel compositions, and methods of drug delivery using the self-assembled gel compositions are also described.
    Type: Application
    Filed: September 23, 2011
    Publication date: October 24, 2013
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Jeffrey M. Karp, Praveen Kumar Vemula, Nathaniel R. Campbell, Abdullah M. Syed, Sufeng Zhang, Omid C. Farokhzad, Robert S. Langer